Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-011603
Filing Date
2023-06-29
Accepted
2023-06-29 16:30:42
Documents
73
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acgn-20230331x10q.htm   iXBRL 10-Q 1578814
2 EX-31.1 acgn-20230331xex31d1.htm EX-31.1 14737
3 EX-32.1 acgn-20230331xex32d1.htm EX-32.1 7168
4 GRAPHIC acgn-20230331x10q004.jpg GRAPHIC 6477
  Complete submission text file 0001558370-23-011603.txt   7720810

Data Files

Seq Description Document Type Size
5 EX-101.SCH acgn-20230331.xsd EX-101.SCH 64765
6 EX-101.CAL acgn-20230331_cal.xml EX-101.CAL 51013
7 EX-101.DEF acgn-20230331_def.xml EX-101.DEF 298289
8 EX-101.LAB acgn-20230331_lab.xml EX-101.LAB 484941
9 EX-101.PRE acgn-20230331_pre.xml EX-101.PRE 441162
67 EXTRACTED XBRL INSTANCE DOCUMENT acgn-20230331x10q_htm.xml XML 1331004
Mailing Address 505 EAGLEVIEW BOULEVARD SUITE 212 EXTON PA 19341
Business Address 505 EAGLEVIEW BOULEVARD SUITE 212 EXTON PA 19341 4843481600
Aceragen, Inc. (Filer) CIK: 0000861838 (see all company filings)

EIN.: 043072298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-31918 | Film No.: 231057823
SIC: 2836 Biological Products, (No Diagnostic Substances)